

Inflammatix, Inc.

Burlingame, CA

<https://inflammatrix.com>

(650) 443-3030

SINCE ITS FOUNDING IN**2016****3 Federal awards & 3 VC rounds****30+ Employees****N/A Socioeconomic Category****9 Patents issued and pending****2019 AACC Disruptive Tech Award**Existing infectious disease diagnostics: “Find the bug”

- Misses 70% of infections (inaccessible)
- Problems w/ emerging & commensal pathogens
- Slow (hours to days) & centralized

HostDx™ testing: read the immune system in < 30min

- Does the patient need antibiotics?
- What other diagnostics are needed?
- Does the patient need to be hospitalized?

Solicitation:*Point-of-care Monitoring of the Host-Pathogen Interaction during Infection***DARPA SBIR Sponsor****SB162-002 Topic Number****Human Impact Primary Innovation****Improved Performance Secondary Innovation****Advanced Single Point-of-Care (POC)**

Infections are often clinically indistinguishable from non-infectious inflammation, and so diagnosis is largely based on clinical suspicion. This uncertainty can lead to delayed/unnecessary treatment with antibiotics and to substantially increased mortality, cost, and antimicrobial resistance.

Inflammatix, Inc. developed the HostDx™ sample-to-answer, simple point-of-care (POC) host-response test system. This flagship **HostDx-Sepsis** diagnostic for sepsis can determine: (1) the likelihood of a bacterial infection, (2) the (separate) likelihood of a viral infection, and (3) the risk of progression to sepsis. Custom algorithms validated in dozens of cohorts with nearly 2,000 patients have demonstrated high accuracy across broad clinical phenotypes - children & adults, broad range of pathogens & severities, in countries around the globe.

IMPACT TO MISSION

The Inflammatix HostDx-Sepsis test can rapidly identify the presence of bacterial or viral infections (including COVID-19) in less than 30 minutes, getting the right therapy to patients quickly. The test could be used in the ~20,000,000 inpatient encounters/year in which a physician needs to rapidly rule-out sepsis.

BEYOND PHASE II

Inflammatix was awarded \$6M on contract with potential of \$72M total from the Biomedical Advanced Research and Development Authority (BARDA) to further enhance its HostDx™ tests. They have secured \$32 million in series C funding to advance to EU launch and FDA clearance. Existing investors include Khosla Ventures, Northpond Ventures and Think-Health. Several further tests are in development, including a host-response risk-stratification (need for hospitalization) test for COVID-19.